Faculty Opinions recommendation of Perventricular device closure of ventricular septal defects: six months results in 30 young children.

Abstract Background: This report presents updated data and mid-term follow-up information to a former study introducing the novel technique of percutaneous-perventricular device closure of doubly committed subarterial ventricular septal defect. Methods: Thirty-eight patients were added to the former series. There were 54 patients in total who had isolated doubly committed subarterial ventricular septal defects and underwent percutaneous-perventricular device closure. Closure outcomes and possible complications were measured in the hospital and during the 2.5-year follow-up. Results: Surgery was successful in 53 patients (98.1%). There was no death, residual shunt, new valve regurgitation or arrhythmia either perioperatively or during the entire follow-up period. Only one patient developed pericardial effusion and tamponade in the former series. The mean hospital stay was 3.2±0.6 days (range, 3.0 to 6.0 days), and only one unsuccessful case needed blood transfusion (1.9%). Conclusions: The percutaneous-perventricular device closure of isolated doubly committed subarterial ventricular septal defects appeared to be safe. Close monitoring for bleeding is essential postoperatively, especially in younger patients. This technique is generally safe with acceptable mid-term follow-up.

Download Full-text

AS-116: Role of Transesophageal Echocardiography in the Hybrid Approach to Perventricular Device Closure of Muscular Ventricular Septal Defects

The American Journal of Cardiology ◽

10.1016/j.amjcard.2009.01.169 ◽

2009 ◽

Vol 103 (9) ◽

pp. 54B

Author(s):

Yuqi Zhang ◽

Kun Sun ◽

Zhiqing Yu ◽

Zhi Fang Zhang ◽

Lan Ping Wu ◽

...

Keyword(s):

Transesophageal Echocardiography ◽

Hybrid Approach ◽

Ventricular Septal Defects ◽

Device Closure ◽

Septal Defects ◽

Perventricular Device Closure

Download Full-text

Multicenter Experience with Perventricular Device Closure of Muscular Ventricular Septal Defects

Pediatric Cardiology ◽

10.1007/s00246-004-0956-2 ◽

2005 ◽

Vol 26 (2) ◽

pp. 169-175 ◽

Cited By ~ 100

Author(s):

E.A. Bacha ◽

Q.-L. Cao ◽

M.E. Galantowicz ◽

J.P. Cheatham ◽

C.E. Fleishman ◽

...

Keyword(s):

Ventricular Septal Defects ◽

Device Closure ◽

Septal Defects ◽

Perventricular Device Closure

Download Full-text

Percutaneous-perventricular device closure of ventricular septal defect: mid-term follow-up.

10.21203/rs.2.16046/v3 ◽

2020 ◽

Author(s):

Long Wang ◽

Lin Xie ◽

Weiqiang Ruan ◽

Tao Li ◽

Changping Gan ◽

...

Keyword(s):

Ventricular Septal Defect ◽

Septal Defect ◽

Close Monitoring ◽

The Novel ◽

Ventricular Septal Defects ◽

Device Closure ◽

Residual Shunt ◽

Septal Defects ◽

Perventricular Device Closure

Abstract Background: This report presents updated data and mid-term follow-up information to a former study introducing the novel technique of percutaneous-perventricular device closure of doubly committed subarterial ventricular septal defect. Methods: Thirty-eight patients were added to the former series. There were 54 patients in total who had isolated doubly committed subarterial ventricular septal defects and underwent percutaneous-perventricular device closure. Closure outcomes and possible complications were measured in the hospital and during the 2.5-year follow-up. Results: Surgery was successful in 53 patients (98.1%). There was no death, residual shunt, new valve regurgitation or arrhythmia either perioperatively or during the entire follow-up period. Only one patient developed pericardial effusion and tamponade in the former series. The mean hospital stay was 3.2±0.6 days (range, 3.0 to 6.0 days), and only one unsuccessful case needed blood transfusion (1.9%). Conclusions: The percutaneous-perventricular device closure of isolated doubly committed subarterial ventricular septal defects appeared to be safe. Close monitoring for bleeding is essential postoperatively, especially in younger patients. This technique is generally safe with acceptable mid-term follow-up.

Download Full-text